IL201433A - Compositions Containing [2 - ({4 - [(Dimethylamino) Imminomethyl] Phenyl} Carbonylamino) -5-Methoxyphenyl] -5-n-Chloro (2-Pyridyl) Carboxamide and Chopidogrel - Google Patents

Compositions Containing [2 - ({4 - [(Dimethylamino) Imminomethyl] Phenyl} Carbonylamino) -5-Methoxyphenyl] -5-n-Chloro (2-Pyridyl) Carboxamide and Chopidogrel

Info

Publication number
IL201433A
IL201433A IL201433A IL20143309A IL201433A IL 201433 A IL201433 A IL 201433A IL 201433 A IL201433 A IL 201433A IL 20143309 A IL20143309 A IL 20143309A IL 201433 A IL201433 A IL 201433A
Authority
IL
Israel
Prior art keywords
iminomethyl
clopidogrel
carbonylamino
carboxamide
methoxyphenyl
Prior art date
Application number
IL201433A
Other languages
English (en)
Hebrew (he)
Other versions
IL201433A0 (en
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of IL201433A0 publication Critical patent/IL201433A0/en
Publication of IL201433A publication Critical patent/IL201433A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL201433A 2007-04-13 2009-10-11 Compositions Containing [2 - ({4 - [(Dimethylamino) Imminomethyl] Phenyl} Carbonylamino) -5-Methoxyphenyl] -5-n-Chloro (2-Pyridyl) Carboxamide and Chopidogrel IL201433A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91185207P 2007-04-13 2007-04-13
PCT/US2008/004760 WO2008127682A2 (en) 2007-04-13 2008-04-11 Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor

Publications (2)

Publication Number Publication Date
IL201433A0 IL201433A0 (en) 2010-05-31
IL201433A true IL201433A (en) 2016-02-29

Family

ID=39638994

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201433A IL201433A (en) 2007-04-13 2009-10-11 Compositions Containing [2 - ({4 - [(Dimethylamino) Imminomethyl] Phenyl} Carbonylamino) -5-Methoxyphenyl] -5-n-Chloro (2-Pyridyl) Carboxamide and Chopidogrel

Country Status (16)

Country Link
US (3) US20080254036A1 (enExample)
EP (2) EP2155195B1 (enExample)
JP (2) JP5469595B2 (enExample)
KR (1) KR101473207B1 (enExample)
CN (2) CN103071154A (enExample)
AU (1) AU2008239659B2 (enExample)
BR (1) BRPI0809655B8 (enExample)
CA (1) CA2683793C (enExample)
DO (1) DOP2009000244A (enExample)
EA (1) EA020531B1 (enExample)
GT (1) GT200900260A (enExample)
IL (1) IL201433A (enExample)
MX (1) MX2009010953A (enExample)
NZ (1) NZ580162A (enExample)
TN (1) TN2009000408A1 (enExample)
WO (1) WO2008127682A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376515B2 (en) * 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7521470B2 (en) * 2004-06-18 2009-04-21 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) * 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN101595092B (zh) 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
KR101509829B1 (ko) * 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
HRP20200445T1 (hr) 2009-11-11 2020-06-12 Chiesi Farmaceutici S.P.A. Metode liječenja ili prevencije tromboze u stentu
WO2011075602A1 (en) * 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
CN104774176A (zh) 2009-12-17 2015-07-15 米伦纽姆医药公司 合成Xa因子抑制剂的方法
CA2784921A1 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
US8663661B2 (en) * 2009-12-23 2014-03-04 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
US20120052058A1 (en) * 2010-08-30 2012-03-01 Emory University Methods of managing the blood coagulation and pharmaceutical compositions related thereto
AR082803A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US10603316B2 (en) 2013-08-21 2020-03-31 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks
WO2015038968A1 (en) * 2013-09-13 2015-03-19 The General Hospital Corporation Activatable fibrin-binding probes
TW201613581A (en) * 2014-09-02 2016-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition for suppression of thromboembolization after stent placement
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
US20190300483A1 (en) * 2016-06-02 2019-10-03 Dr. Reddy's Laboratories Limited POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
CN110740736A (zh) 2017-06-23 2020-01-31 奇斯药制品公司 预防体-肺动脉分流术血栓形成的方法
WO2020047097A1 (en) * 2018-08-28 2020-03-05 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks
CN116782911A (zh) * 2020-09-17 2023-09-19 艾克赛特赫拉制药有限责任公司 治疗性化合物、组合物及其使用方法
EP4070658A1 (de) * 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76346A (en) 1994-04-26 1997-08-28 Selectide Corp Factor xa inhibitors
ES2216625T3 (es) * 1998-11-27 2004-10-16 ABBOTT GMBH & CO. KG Bencimidazoles substituidos y su empleo como inhibidores de parp.
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
JP4744050B2 (ja) * 1999-09-17 2011-08-10 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ベンズアミドおよび関連するＸａ因子阻害剤
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
BR0014078A (pt) * 1999-09-17 2002-12-31 Millennium Pharm Inc Inibidores de fator xa
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7312043B2 (en) * 2000-07-10 2007-12-25 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
HRP20000765A2 (en) 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
DE10065475A1 (de) * 2000-12-28 2002-07-18 Switch Biotech Ag Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion
AU2002258394A1 (en) * 2001-02-07 2002-09-12 Bristol-Myers Squibb Company Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam3
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
US20030129193A1 (en) * 2001-09-27 2003-07-10 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coaguligand treatment
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
FR2838057B1 (fr) * 2002-04-05 2005-07-08 Servier Lab Nouvelle association d'un antithrombotique et d'aspirine
US20040067995A1 (en) * 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
EP1663239A4 (en) * 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
FR2860436B1 (fr) * 2003-10-03 2006-01-20 Servier Lab Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire
US7022695B2 (en) * 2003-10-09 2006-04-04 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of Factor Xa
DE102004016845A1 (de) * 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
US7521470B2 (en) * 2004-06-18 2009-04-21 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DE102004046623A1 (de) * 2004-09-25 2006-03-30 Bayer Healthcare Ag Neue Pyrimidin-Derivate und ihre Verwendung
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung
JPWO2006137510A1 (ja) * 2005-06-24 2009-01-22 小野薬品工業株式会社 脳血管障害時における出血低減剤
CN102336702B (zh) * 2005-11-08 2015-02-11 米伦纽姆医药公司 Xa因子抑制剂n-(5-氯-2-吡啶基)-2-[[4-[(二甲氨基)亚氨基甲基]苯甲酰基]氨基]-5-甲氧基-苯甲酰胺的医药盐和多晶型
WO2007112367A2 (en) 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN101595092B (zh) * 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
EP2101760B1 (en) * 2006-12-08 2013-02-27 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
JP2010515691A (ja) * 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
KR101509829B1 (ko) * 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법

Also Published As

Publication number Publication date
US20080254036A1 (en) 2008-10-16
MX2009010953A (es) 2009-10-29
CA2683793A1 (en) 2008-10-23
CN103071154A (zh) 2013-05-01
GT200900260A (es) 2011-09-05
EP2155195A2 (en) 2010-02-24
BRPI0809655B8 (pt) 2021-05-25
EA200970946A1 (ru) 2010-04-30
EP2155195B1 (en) 2014-07-16
US20120046230A1 (en) 2012-02-23
AU2008239659A1 (en) 2008-10-23
US8455440B2 (en) 2013-06-04
WO2008127682A2 (en) 2008-10-23
WO2008127682A3 (en) 2009-05-07
BRPI0809655A2 (pt) 2014-10-07
EA020531B1 (ru) 2014-11-28
TN2009000408A1 (en) 2011-03-31
HK1141230A1 (en) 2010-11-05
KR101473207B1 (ko) 2014-12-16
KR20100016428A (ko) 2010-02-12
DOP2009000244A (es) 2010-02-28
CN101743001B (zh) 2013-02-06
EP2591783A1 (en) 2013-05-15
NZ580162A (en) 2012-10-26
IL201433A0 (en) 2010-05-31
JP2010523679A (ja) 2010-07-15
US20130315897A1 (en) 2013-11-28
BRPI0809655B1 (pt) 2019-09-10
JP2013177459A (ja) 2013-09-09
AU2008239659B2 (en) 2013-09-05
JP5469595B2 (ja) 2014-04-16
CA2683793C (en) 2016-09-20
CN101743001A (zh) 2010-06-16

Similar Documents

Publication Publication Date Title
IL201433A (en) Compositions Containing [2 - ({4 - [(Dimethylamino) Imminomethyl] Phenyl} Carbonylamino) -5-Methoxyphenyl] -5-n-Chloro (2-Pyridyl) Carboxamide and Chopidogrel
EP2068667A4 (en) TEMPERATURE-MODIFYING GARMENT AND METHODS OF USING THE SAME
IL196313A0 (en) Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents
IL199024A (en) Pesticides containing anthranilamide compounds and their use
SI2012839T1 (sl) Novi antimikrobni substrati in njihova uporaba
IL178894A0 (en) Therapeutic antimicrobial compositions and methods
IL198231A0 (en) Pyridine carboxamides as 11??hsd1 inhibitors
IL187257A0 (en) Compositions and methods for inhibition of the jak pathway
PL2085387T3 (pl) Nowe pochodne 1,2-dihydrochinoliny zawierające jako podstawniki fenylochalkogeno-podstawioną niższą grupę alkilową oraz wprowadzoną przez ester grupę fenylową
PL2057153T3 (pl) POCHODNE (3-ARYLO-PIPERAZYN-1-YLOWE) 6,7-DIALKOKSYCHINAZOLINY, 6,7-DIALKOKSYFTALAZYNY i 6,7-DIALKOKSYIZOCHINOLINY
IL183666A0 (en) Amide prodrug of gemcitabine, compositions and use thereof
AP2008004649A0 (en) Quinoline derivatives and their use as pesticides
IL200102A0 (en) 6-benzyl-3,3 dimethyl-2,3,4,7-tetrahydro-indolo{2,3-c} quinoline compounds, compositions containing the same and uses thereof
IL192988A (en) History of Amoebic Hepatitis, Methods of Preparation, Pharmaceutical Preparations Containing and Uses
ATE502682T1 (de) Zusammensetzung zur feuerbekämpfung und formulierungen aus dieser zusammensetzung
PL1814977T3 (pl) Kompozycje na bazie arthrospira i ich zastosowania
EP1765321A4 (en) ANTIMICROBIAL COMPOSITIONS AND METHOD OF USE THEREOF
SI2056799T1 (sl) Sestavki in postopki za zdravljenje ali preprečevanje glavkoma ali njegovega napredovanja
GB2455026B (en) Trousers
GB0622399D0 (en) Novel compositions and uses thereof
SI1802209T1 (sl) Oblačilo
ZA200900231B (en) (S)-(-)-amlodipine camsylate or hydrate thereof and pharmaceutical composition comprising same
GB0814753D0 (en) Amide derivatives as ion-channel ligands and pharamaceutical compositions and methods of using the same
EP1802280A4 (en) CLOPIDOGREL COMPOSITIONS
GB0622400D0 (en) Novel compositions and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed